Gail S. Wright

6.5k citations

19 papers · 3.6k indexed · 1 hit paper · h-index 13

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- CAR-T cell therapy research
Cancer Research top 2%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies

Papers in ⓘ

Structural Biology 1
Oncology 16
- Cancer Treatment and Pharmacology 5
- HER2/EGFR in Cancer Research 4
- PARP inhibition in cancer therapy 4
- Colorectal Cancer Treatments and Studies 2

Co-authors: Hope S. Rugo (3 shared papers)Seock‐Ah Im (2 shared papers)Sylvia Adams (1 shared paper)Luciana Molinero (1 shared paper)Volkmar Henschel (1 shared paper)Véronique Dièras (1 shared paper)Peter Schmid (1 shared paper)Leisha A. Emens (1 shared paper)
Journals: Gynecologic Oncology (4 papers)Cancer Research (4 papers)Clinical Cancer Research (2 papers)Journal of Clinical Oncology (2 papers)Clinical Breast Cancer (1 paper)
Partner nations: United States Croatia Serbia

In The Last Decade

Gail S. Wright

16 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer 2018 · 3.0k citations

Peers

Countries citing papers authored by Gail S. Wright

Since Specialization

Citations

This map shows the geographic impact of Gail S. Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail S. Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail S. Wright more than expected).

Fields of papers citing papers by Gail S. Wright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail S. Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail S. Wright. The network helps show where Gail S. Wright may publish in the future.

Co-authors

The 25 scholars most cited alongside Gail S. Wright, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gail S. Wright Line = papers co-authored together Gail S. Wright links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer New England Journal of Medicine ·Peter Schmid, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Roberto Hegg, Seock‐Ah Im, Gail S. Wright, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Roel Funke, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens Hit paper breakdown →	2018	3005
2	Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Craig H. Reynolds, Coleman K. Obasaju, Michael J. Schell, Xueli Li, Zhong Zheng, David Boulware, J. R. Caton, Linda C. DeMarco, Mark Allen O’Rourke, Gail S. Wright, Kristi A. Boehm, Lina Asmar, Jane Bromund, Guangbin Peng, Matthew Monberg, Gerold Bepler	2009	138
3	Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial The Lancet Oncology ·Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Yang Zhao, Joyce Antal, Shannon R. Morris, Joyce O’Shaughnessy	2019	86
4	Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597 Journal of Clinical Oncology ·Daniel D. Karp, Sandra J. Lee, Steven M. Keller, Gail S. Wright, Seena C. Aisner, Steven A. Belinsky, David H. Johnson, Michael R. Johnston, Gary E. Goodman, Gerald H. Clamon, Gordon Okawara, Randolph S. Marks, Éric Fréchette, Worta McCaskill‐Stevens, Scott M. Lippman, John Ruckdeschel, Fadlo R. Khuri	2013	82
5	OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab Gynecologic Oncology ·Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton, Evelyn Fleming, J Belotte, Erika Krasnickas Keeton, Ping Wang, Divya Gupta, Aine Clements, Heidi J. Gray, Gottfried E. Konecny, Richard G. Moore, Debra L. Richardson	2022	44
6	Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors Clinical Cancer Research ·R. Bagatell, Cynthia E. Herzog, Tanya Trippett, Joseph F. Grippo, Georgina Cirrincione‐Dall, Elizabeth Fox, Margaret E. Macy, J. Bish, Patricia Whitcomb, Alberta Aikin, Gail S. Wright, Sergey Yurasov, Frank M. Balis, Lia Gore	2010	41
7	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study npj Breast Cancer ·Linda T. Vahdat, Peter Schmid, Andres Forero‐Torres, Kimberly Blackwell, Melinda L. Telli, Michelle Melisko, Volker Möbus, Javier Cortés, Alberto J. Montero, X. Cynthia, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel‐Baset Halim, Christopher D. Turner, Denise A. Yardley	2021	39
8	Early detection and prevention of lung cancer Current Opinion in Oncology ·Gail S. Wright, Michael E. Gruidl	2000	36
9	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation Breast Cancer Research and Treatment ·Joyce O’Shaughnessy, Angela DeMichele, X. Cynthia, Paul Richards, Denise A. Yardley, Gail S. Wright, Kevin Kalinsky, Ronald G. Steis, Sami Diab, Gerard T. Kennealey, Ryan Geschwindt, Wei Jiang, Hope S. Rugo	2018	35
10	Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer Clinical Breast Cancer ·Andrew D. Seidman, Alison Conlin, Ariadne M. Bach, Mary Ellen Moynahan, Diana Lake, Andres Forero, Gail S. Wright, Mary Helen Hackney, Alicia Clawson, Larry Norton, Clifford A. Hudis	2013	29
11	Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study Clinical Cancer Research ·Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Jie Xiao, Jessica A. Sorrentino, Janet K. Horton, Joyce O’Shaughnessy	2021	28
12	Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis Cancer Research ·Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Javier Cortés, Giuseppe Curigliano, Mark D. Pegram, Antonino Musolino, Thomas Bachelot, Gail S. Wright, Michelino De Laurentiis, Peter A. Kaufman, Timothy Pluard, Francesco Ricci, Lupe G. Salazar, Denise A. Yardley, Sutton Edlich, Shengyan Hong, Edwin P. Rock, William J. Gradishar, (unknown)	2020	28
13	Phase II OVARIO Study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab Gynecologic Oncology ·Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton, Evelyn Fleming, J Belotte, Erika Krasnickas Keeton, Jian Chen, Aine Clements, Heidi J. Gray, Gottfried E. Konecny, Richard G. Moore, Debra L. Richardson	2021	13
14	Abstract PD1-06: Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial Cancer Research ·Joyce O’Shaughnessy, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Jie Xiao, Jessica A. Sorrentino, Janet K. Horton, Antoinette R. Tan	2021	6
15	Abstract RF01-04: Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification Cancer Research ·Senthil Damodaran, Fabrice André, Nisha Unni, Marta Ferreira, Karthik V. Giridhar, Brooke Daniel, Marco Colleoni, Luís Costa, Thomas Bachelot, Ciara O’Brien, Gail S. Wright, Masashi Shimura, Gareth Tomlinson, Maciej Gil, Nicholas C. Turner	2024	5
16	Abstract CT107: Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Efficacy and safety results from phase II of the TRINITI-1 study Cancer Research ·Stacy Moulder, Megan Karuturi, Denise A. Yardley, Gail S. Wright, Sara A. Hurvitz, Rebecca Moroose, Tara Sanft, X. Cynthia, Amelia Zelnak, Angela DeMichele, Amy S. Clark, Das Purkayastha, Alisha Khullar, N. Caria, Aditya Bardia	2018	3
17	A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO Gynecologic Oncology ·Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton, Evelyn Fleming, J Belotte, Shelby Gorman, Natalie Compton, Aine Clements, Heidi J. Gray, Gottfried E. Konecny, Richard G. Moore, Debra L. Richardson	2025	0
18	Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial Annals of Oncology ·Joyce O’Shaughnessy, Gail S. Wright, AR Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Jessica A. Sorrentino, Yang Zhao, Janet K. Horton, Antoinette R. Tan	2019	0
19	OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039) Gynecologic Oncology ·Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton, Evelyn Fleming, J Belotte, Erika Krasnickas Keeton, Ping Wang, Aine Clements, Heidi J. Gray, Gottfried E. Konecny, Richard G. Moore, Debra L. Richardson	2022	0

About Gail S. Wright

Gail S. Wright is a scholar working on Structural Biology, Oncology, Reproductive Medicine, Genetics and Cancer Research, having authored 19 papers that have together received 3.6k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (4 papers), PARP inhibition in cancer therapy (4 papers), Ovarian cancer diagnosis and treatment (4 papers), Colorectal Cancer Treatments and Studies (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Oncology (2.7k citations), Cancer Research (817 citations), Immunology (920 citations), Pulmonary and Respiratory Medicine (1.1k citations) and Genetics (144 citations). Gail S. Wright has collaborated with scholars based in United States, Croatia and Serbia. Frequent co-authors include Hope S. Rugo, Seock‐Ah Im, Sylvia Adams, Luciana Molinero, Volkmar Henschel, Véronique Dièras, Peter Schmid, Leisha A. Emens, Carlos H. Barrios and Sherene Loi. Their work appears in journals such as Gynecologic Oncology, Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology and Clinical Breast Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact